NEW YORK, August 6, 2026, 10:14 EDT — U.S. markets open.
Becton, Dickinson and Company NYSE:BDX rose 3.8% to $177.22 in late morning trading on Thursday. Shares advanced after the firm posted stronger-than-expected quarterly results and slightly lifted its profit outlook.
The earnings outperformance was minor, but the shift in cash flow was substantial. Free cash flow for the nine-month period increased 44.6% to $1.73 billion, as adjusted EPS slipped 0.7%.
Nonetheless, the gains did not originate from profits. Outflows for working capital and other items fell by $564 million, surpassing the company-reported $532 million overall boost in free cash flow. This puts fourth-quarter cash conversion as the more significant gauge for investors.
The quarter surpassed both consensus expectations.
| Fiscal third-quarter metric | Actual | Consensus | Surprise | Year earlier | Year-on-year |
|---|---|---|---|---|---|
| Revenue | $4.983 billion | $4.89 billion | +1.9% | $4.726 billion | +5.4% |
| Adjusted diluted EPS | $3.23 | $3.14 | +2.9% | $3.08 | +4.9% |
Chief Executive Tom Polen stated that revenue, adjusted operating margin, and adjusted EPS each surpassed internal projections. He called the period New BD’s inaugural complete quarter.
BD increased its adjusted EPS outlook to $12.62 to $12.72, up from the previous range of $12.52 to $12.72. The company maintained its revenue forecast, anticipating growth close to the upper end of the guidance range.
The response was limited to the company. BDX outperformed four comparable peers in the medical-device and hospital-products sector during after-hours trading.
| Company | Delayed price | Intraday change |
|---|---|---|
| Becton Dickinson | $177.22 | up 3.84% |
| Abbott Laboratories NYSE:ABT | $106.54 | up 0.79% |
| Medtronic plc NYSE:MDT | $86.27 | up 0.33% |
| Stryker Corporation NYSE:SYK | $337.08 | up 0.01% |
| Baxter International Inc. NYSE:BAX | $27.35 | up 0.07% |
Revenue expanded across the board, though performance varied. Interventional and BioPharma Systems delivered the strongest gains when excluding currency impacts.
| Business segment | Quarterly revenue | Reported growth | Currency-neutral growth |
|---|---|---|---|
| Medical Essentials | $1.675 billion | up 4.5% | up 3.2% |
| Connected Care | $1.224 billion | up 4.9% | up 4.4% |
| BioPharma Systems | $670 million | up 6.6% | up 5.2% |
| Interventional | $1.414 billion | up 6.4% | up 5.5% |
The geographic divide became more pronounced. U.S. revenue increased by 6.9% on a currency-neutral basis, while international revenue edged up 0.6%. Advanced Patient Monitoring posted growth of 11.2%, whereas Medication Delivery gained 1.6%.
The cash bridge for the nine-month period highlights why the rally remains unconfirmed. Free cash flow increased even as adjusted earnings and continuing income declined.
| Nine-month cash indicator | Fiscal 2026 | Fiscal 2025 | Change |
|---|---|---|---|
| Income from continuing operations | $725 million | $755 million | Down 4.0% |
| Working-capital and other outflow | $(319) million | $(883) million | $564 million decrease in outflow |
| Operating cash flow | $2.104 billion | $1.578 billion | Up 33.3% |
| Capital expenditure | $(376) million | $(383) million | Falls by 1.7% |
| Free cash flow | $1.728 billion | $1.195 billion | Rises 44.6% |
| Adjusted diluted EPS | $8.59 | $8.65 | Off 0.7% |
| Free cash flow per diluted share | $6.14 | $4.14 | Up 48.2% |
Based on free cash flow and the average number of diluted shares.
Capital allocation activity was robust. BD paid back $2.70 billion in debt and bought back $2.25 billion worth of shares. The company also obtained a $3.86 billion distribution from the spun-off entity.
On February 9, BD finalized merging its prior biosciences and diagnostics units with Waters Corporation NYSE:WAT. Earlier periods have been restated to reflect continuing operations.
FactSet’s latest recommendation split showed a cautious optimism. Out of 15 analysts, eight assigned a Hold rating to BDX, while seven issued a Buy or Overweight. These numbers are subject to change after Thursday’s results.
| Analyst recommendation | Current | One month earlier | Current share |
|---|---|---|---|
| Buy | 6 | 7 | 40.0% |
| Overweight | 1 | 0 | 6.7% |
| Hold | 8 | 10 | 53.3% |
| Underweight | 0 | 0 | 0% |
| Sell | 0 | 0 | 0% |
| Consensus | Overweight | Overweight | — |
FactSet reported a median price target of $177.50 and an average price target of $178.20. These figures were just 0.2% and 0.6% higher than the morning’s quoted price. This indicates minimal target-related upside absent any updates.
Risks: The increase in cash flow was driven by reduced working-capital outflows. International expansion stayed sluggish. The results may face challenges from tariffs, China’s volume-based procurement, and the timing of Alaris remediation.
The earnings beat offered some reassurance. A sustained rerating depends on stable cash generation that continues without further working-capital releases.
